Oral semaglutide lowered HbA1c vs placebo in a phase 3 trial in adolescents with type 2 diabetes, pending full data and ...
With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled ...
A phase 3 trial has shown efficacy in type 2 diabetes for adolescents, positioning it as a potential first oral solution for ...
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years with type 2 diabetes, addressing a significant unmet need. The trial demonstrated a ...
Hosted on MSN
Novel GLP-1 pill tops oral semaglutide for diabetes
An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ...
As weight‑loss drugs surge in popularity, a study raises a new question about what patients may be losing along the way.
Novo Nordisk NVO announced positive top-line data from a late-stage study in its global REIMAGINE clinical study program for a next-generation pipeline candidate, CagriSema, for treating adults with ...
iip<0.001 vs. oral semaglutide 14 mg iiip<0.01 vs. oral semaglutide 14 mg ivBody weight for orforglipron 12 mg vs. oral semaglutide 14 mg and percentage of ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist. Topline data were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results